Consistently, DNMT3A, TET2, and ASXL1 mutations, which are most commonly associated with age-related clonal hematopoiesis, during complete remission phase did not increase risk of relapse in AML41, whereas other mutations such as U2AF1 and RUNX1 (absent in CH) could associate with relapse and lower rates of relapse-free survival6,42. Here, TET2 is linked to cyclic hematopoiesis.